Pay in 4 interest-free payments of $5.71 Learn more
Ships within 48 hours · Estimated delivery Oct 3 - Oct 8
Health and safety risks Using unregulated or compounded peptides carries potential risks, including contamination, dosing inaccuracies, and unknown long-term effects
Sermorelin is a synthetic form of growth hormonereleasing hormone (GHRH)
Given IGF-1 LR3's sensitivity and the significant investment involved, verification provides important assurance
mechanism unexplained Relative contributions of direct peptide effects versus downstream IGF-1 actions inadequately characterized Long-term receptor sensitivity and potential for desensitization inadequately studied Individual patient variability in response not well-characterized Potential for differential effects based on endogenous growth hormone status unclear Long-Term Safety Considerations Critical safety questions remain unanswered regarding chronic peptide administration: Cardiovascular safety concerns FDA warnings cite risks of increased heart rate, systemic vasodilation, flushing, and transient hypotension Immunogenicity risks FDA identifies both peptides as potentially immunogenic with risk of serious immune reactions including anaphylaxis Cancer risk theoretical concern that chronic growth hormone/IGF-1 elevation could promote cellular proliferation
Metabolic Risk (Lower): Due to its very short half-life (approximately 20 minutes), IGF-1 DES poses a lower risk of sustained, systemic hypoglycemia compared to the long-acting IGF-1 LR3
